On Wednesday, I forwarded the argument of an analyst that Medtronic's (NYSE:MDT) controversial bone graft product Infuse will likely live on in a diminished form, even if an independent review confirms its safety. So the obvious question is, who will fill the void left by Infuse?

Medtronic’s controversial bone growth product Infuse has been hammered by quarter after quarter of declining sales. Currently, Yale reviewers are conducting an independent review of the data related to Infuse. The review’s conclusions are eagerly awaited by Medtronic CEO Omar Ishrak who hopes that Infuse will be vindicated once and for all thereby silencing those who have [...]

NEW YORK, Feb. 1, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell Therapy - Technologies, Markets and...